Retigabine is being developed as an adjunctive treatment for partial-onset seizures in patients with epilepsy. It has an entirely new mechanism of action and works as both a potassium channel opener and potentiates the effects of GABA, which Valeant believes will be a key product advantage where poly-therapy is common.
ChemNet is a registered trademark of Zhejiang NetSun Co., Ltd.
Global Chemical Exchange, China Chemical Network and ChemNet.com are services
of Zhejiang NetSun Co., Ltd.